Impact of TGF-[beta]1 -509C/T and 869T/C polymorphisms on glioma risk and patient prognosis
Transforming growth factor beta (TGF-[beta]) plays an important role in carcinogenesis. Two polymorphisms in the TGF-[beta]1 gene (-509C/T and 869T/C) were described to influence susceptibility to gastric and breast cancers. The 869T/C polymorphism was also associated with overall survival in breast...
Gespeichert in:
| Veröffentlicht in: | Tumor biology 2015-08, Vol.36 (8), p.6525 |
|---|---|
| Hauptverfasser: | , , , , , , , , , |
| Format: | Artikel |
| Sprache: | eng |
| Schlagworte: | |
| Online-Zugang: | Volltext |
| Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
| container_end_page | |
|---|---|
| container_issue | 8 |
| container_start_page | 6525 |
| container_title | Tumor biology |
| container_volume | 36 |
| creator | Vieira De Castro, Joana Gonçalves, Céline S Costa, Sandra Linhares, Paulo Vaz, Rui Nabiço, Ricardo Amorim, Júlia Viana-pereira, Marta Reis, Rui M Costa, Bruno M |
| description | Transforming growth factor beta (TGF-[beta]) plays an important role in carcinogenesis. Two polymorphisms in the TGF-[beta]1 gene (-509C/T and 869T/C) were described to influence susceptibility to gastric and breast cancers. The 869T/C polymorphism was also associated with overall survival in breast cancer patients. In the present study, we investigated the relevance of these TGF-[beta]1 polymorphism in glioma risk and prognosis. A case-control study that included 114 glioma patients and 138 cancer-free controls was performed. Single nucleotide polymorphisms (SNPs) were evaluated by polymerase chain reaction followed by restriction fragment length polymorphism (PCR-RFLP). Univariate and multivariate logistic regression analyses were used to calculate odds ratio (OR) and 95 % confidence intervals (95 % CI). The influence of TGF-[beta]1-509C/T and 869T/C polymorphisms on glioma patient survival was evaluated by a Cox regression model adjusted for patients' age and sex and represented in Kaplan-Meier curves. Our results demonstrated that TGF-[beta]1 gene polymorphisms -509C/T and 869T/C are not significantly associated with glioma risk. Survival analyses showed that the homozygous -509TT genotype associates with longer overall survival of glioblastoma (GBM) patients when compared with patients carrying CC+CT genotypes (OR, 2.41; 95 % CI, 1.06-5.50; p=0.036). In addition, the homozygous 869CC genotype is associated with increased overall survival of GBM patients when compared with 869TT+TC genotypes (OR, 2.62; 95 % CI, 1.11-6.17; p=0.027). In conclusion, this study suggests that TGF-[beta]1-509C/T and 869T/C polymorphisms are not significantly associated with risk for developing gliomas but may be relevant prognostic biomarkers in GBM patients. |
| doi_str_mv | 10.1007/s13277-015-3343-0 |
| format | Article |
| fullrecord | <record><control><sourceid>proquest</sourceid><recordid>TN_cdi_proquest_journals_1706017487</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>3785385251</sourcerecordid><originalsourceid>FETCH-proquest_journals_17060174873</originalsourceid><addsrcrecordid>eNqNykFuwjAQhWGrKlIp9ADdjdS1m5k4xMk6Ki377BBCbhvAkNhuxiy4PVbFAVi9X3qfEK-E74SoMyaVay2RFlKpQkl8EFMq8hSqwsfUSCiLvFJP4pn5iAnWdTkV69UQzE8Ev4P2cynX3100GwK5wLrJWjDuF6qybrMGgu8vgx_DwfLA4B3se-sHA6Pl078LJtrORQij3zvPludisjM9dy-3nYm35UfbfMkk_s4dx-3Rn0eXri1pLJF0UWl1n7oCj_5G0A</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>1706017487</pqid></control><display><type>article</type><title>Impact of TGF-[beta]1 -509C/T and 869T/C polymorphisms on glioma risk and patient prognosis</title><source>SpringerNature Journals</source><creator>Vieira De Castro, Joana ; Gonçalves, Céline S ; Costa, Sandra ; Linhares, Paulo ; Vaz, Rui ; Nabiço, Ricardo ; Amorim, Júlia ; Viana-pereira, Marta ; Reis, Rui M ; Costa, Bruno M</creator><creatorcontrib>Vieira De Castro, Joana ; Gonçalves, Céline S ; Costa, Sandra ; Linhares, Paulo ; Vaz, Rui ; Nabiço, Ricardo ; Amorim, Júlia ; Viana-pereira, Marta ; Reis, Rui M ; Costa, Bruno M</creatorcontrib><description>Transforming growth factor beta (TGF-[beta]) plays an important role in carcinogenesis. Two polymorphisms in the TGF-[beta]1 gene (-509C/T and 869T/C) were described to influence susceptibility to gastric and breast cancers. The 869T/C polymorphism was also associated with overall survival in breast cancer patients. In the present study, we investigated the relevance of these TGF-[beta]1 polymorphism in glioma risk and prognosis. A case-control study that included 114 glioma patients and 138 cancer-free controls was performed. Single nucleotide polymorphisms (SNPs) were evaluated by polymerase chain reaction followed by restriction fragment length polymorphism (PCR-RFLP). Univariate and multivariate logistic regression analyses were used to calculate odds ratio (OR) and 95 % confidence intervals (95 % CI). The influence of TGF-[beta]1-509C/T and 869T/C polymorphisms on glioma patient survival was evaluated by a Cox regression model adjusted for patients' age and sex and represented in Kaplan-Meier curves. Our results demonstrated that TGF-[beta]1 gene polymorphisms -509C/T and 869T/C are not significantly associated with glioma risk. Survival analyses showed that the homozygous -509TT genotype associates with longer overall survival of glioblastoma (GBM) patients when compared with patients carrying CC+CT genotypes (OR, 2.41; 95 % CI, 1.06-5.50; p=0.036). In addition, the homozygous 869CC genotype is associated with increased overall survival of GBM patients when compared with 869TT+TC genotypes (OR, 2.62; 95 % CI, 1.11-6.17; p=0.027). In conclusion, this study suggests that TGF-[beta]1-509C/T and 869T/C polymorphisms are not significantly associated with risk for developing gliomas but may be relevant prognostic biomarkers in GBM patients.</description><identifier>ISSN: 1010-4283</identifier><identifier>EISSN: 1423-0380</identifier><identifier>DOI: 10.1007/s13277-015-3343-0</identifier><language>eng</language><publisher>London: Springer Nature B.V</publisher><subject>Brain cancer ; Genotype & phenotype ; Growth factors ; Medical prognosis ; Polymorphism ; Risk factors</subject><ispartof>Tumor biology, 2015-08, Vol.36 (8), p.6525</ispartof><rights>International Society of Oncology and BioMarkers (ISOBM) 2015</rights><lds50>peer_reviewed</lds50><oa>free_for_read</oa><woscitedreferencessubscribed>false</woscitedreferencessubscribed></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><link.rule.ids>314,780,784,27924,27925</link.rule.ids></links><search><creatorcontrib>Vieira De Castro, Joana</creatorcontrib><creatorcontrib>Gonçalves, Céline S</creatorcontrib><creatorcontrib>Costa, Sandra</creatorcontrib><creatorcontrib>Linhares, Paulo</creatorcontrib><creatorcontrib>Vaz, Rui</creatorcontrib><creatorcontrib>Nabiço, Ricardo</creatorcontrib><creatorcontrib>Amorim, Júlia</creatorcontrib><creatorcontrib>Viana-pereira, Marta</creatorcontrib><creatorcontrib>Reis, Rui M</creatorcontrib><creatorcontrib>Costa, Bruno M</creatorcontrib><title>Impact of TGF-[beta]1 -509C/T and 869T/C polymorphisms on glioma risk and patient prognosis</title><title>Tumor biology</title><description>Transforming growth factor beta (TGF-[beta]) plays an important role in carcinogenesis. Two polymorphisms in the TGF-[beta]1 gene (-509C/T and 869T/C) were described to influence susceptibility to gastric and breast cancers. The 869T/C polymorphism was also associated with overall survival in breast cancer patients. In the present study, we investigated the relevance of these TGF-[beta]1 polymorphism in glioma risk and prognosis. A case-control study that included 114 glioma patients and 138 cancer-free controls was performed. Single nucleotide polymorphisms (SNPs) were evaluated by polymerase chain reaction followed by restriction fragment length polymorphism (PCR-RFLP). Univariate and multivariate logistic regression analyses were used to calculate odds ratio (OR) and 95 % confidence intervals (95 % CI). The influence of TGF-[beta]1-509C/T and 869T/C polymorphisms on glioma patient survival was evaluated by a Cox regression model adjusted for patients' age and sex and represented in Kaplan-Meier curves. Our results demonstrated that TGF-[beta]1 gene polymorphisms -509C/T and 869T/C are not significantly associated with glioma risk. Survival analyses showed that the homozygous -509TT genotype associates with longer overall survival of glioblastoma (GBM) patients when compared with patients carrying CC+CT genotypes (OR, 2.41; 95 % CI, 1.06-5.50; p=0.036). In addition, the homozygous 869CC genotype is associated with increased overall survival of GBM patients when compared with 869TT+TC genotypes (OR, 2.62; 95 % CI, 1.11-6.17; p=0.027). In conclusion, this study suggests that TGF-[beta]1-509C/T and 869T/C polymorphisms are not significantly associated with risk for developing gliomas but may be relevant prognostic biomarkers in GBM patients.</description><subject>Brain cancer</subject><subject>Genotype & phenotype</subject><subject>Growth factors</subject><subject>Medical prognosis</subject><subject>Polymorphism</subject><subject>Risk factors</subject><issn>1010-4283</issn><issn>1423-0380</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2015</creationdate><recordtype>article</recordtype><sourceid>8G5</sourceid><sourceid>ABUWG</sourceid><sourceid>AFKRA</sourceid><sourceid>AZQEC</sourceid><sourceid>BENPR</sourceid><sourceid>CCPQU</sourceid><sourceid>DWQXO</sourceid><sourceid>GNUQQ</sourceid><sourceid>GUQSH</sourceid><sourceid>M2O</sourceid><recordid>eNqNykFuwjAQhWGrKlIp9ADdjdS1m5k4xMk6Ki377BBCbhvAkNhuxiy4PVbFAVi9X3qfEK-E74SoMyaVay2RFlKpQkl8EFMq8hSqwsfUSCiLvFJP4pn5iAnWdTkV69UQzE8Ev4P2cynX3100GwK5wLrJWjDuF6qybrMGgu8vgx_DwfLA4B3se-sHA6Pl078LJtrORQij3zvPludisjM9dy-3nYm35UfbfMkk_s4dx-3Rn0eXri1pLJF0UWl1n7oCj_5G0A</recordid><startdate>20150801</startdate><enddate>20150801</enddate><creator>Vieira De Castro, Joana</creator><creator>Gonçalves, Céline S</creator><creator>Costa, Sandra</creator><creator>Linhares, Paulo</creator><creator>Vaz, Rui</creator><creator>Nabiço, Ricardo</creator><creator>Amorim, Júlia</creator><creator>Viana-pereira, Marta</creator><creator>Reis, Rui M</creator><creator>Costa, Bruno M</creator><general>Springer Nature B.V</general><scope>3V.</scope><scope>7T5</scope><scope>7TO</scope><scope>7X7</scope><scope>7XB</scope><scope>88E</scope><scope>8AO</scope><scope>8C1</scope><scope>8FE</scope><scope>8FH</scope><scope>8FI</scope><scope>8FJ</scope><scope>8FK</scope><scope>8G5</scope><scope>ABUWG</scope><scope>AFKRA</scope><scope>AZQEC</scope><scope>BBNVY</scope><scope>BENPR</scope><scope>BHPHI</scope><scope>CCPQU</scope><scope>DWQXO</scope><scope>FYUFA</scope><scope>GHDGH</scope><scope>GNUQQ</scope><scope>GUQSH</scope><scope>H94</scope><scope>HCIFZ</scope><scope>K9.</scope><scope>LK8</scope><scope>M0S</scope><scope>M1P</scope><scope>M2O</scope><scope>M7P</scope><scope>MBDVC</scope><scope>PIMPY</scope><scope>PQEST</scope><scope>PQQKQ</scope><scope>PQUKI</scope><scope>PRINS</scope><scope>Q9U</scope></search><sort><creationdate>20150801</creationdate><title>Impact of TGF-[beta]1 -509C/T and 869T/C polymorphisms on glioma risk and patient prognosis</title><author>Vieira De Castro, Joana ; Gonçalves, Céline S ; Costa, Sandra ; Linhares, Paulo ; Vaz, Rui ; Nabiço, Ricardo ; Amorim, Júlia ; Viana-pereira, Marta ; Reis, Rui M ; Costa, Bruno M</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-proquest_journals_17060174873</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2015</creationdate><topic>Brain cancer</topic><topic>Genotype & phenotype</topic><topic>Growth factors</topic><topic>Medical prognosis</topic><topic>Polymorphism</topic><topic>Risk factors</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Vieira De Castro, Joana</creatorcontrib><creatorcontrib>Gonçalves, Céline S</creatorcontrib><creatorcontrib>Costa, Sandra</creatorcontrib><creatorcontrib>Linhares, Paulo</creatorcontrib><creatorcontrib>Vaz, Rui</creatorcontrib><creatorcontrib>Nabiço, Ricardo</creatorcontrib><creatorcontrib>Amorim, Júlia</creatorcontrib><creatorcontrib>Viana-pereira, Marta</creatorcontrib><creatorcontrib>Reis, Rui M</creatorcontrib><creatorcontrib>Costa, Bruno M</creatorcontrib><collection>ProQuest Central (Corporate)</collection><collection>Immunology Abstracts</collection><collection>Oncogenes and Growth Factors Abstracts</collection><collection>Health & Medical Collection</collection><collection>ProQuest Central (purchase pre-March 2016)</collection><collection>Medical Database (Alumni Edition)</collection><collection>ProQuest Pharma Collection</collection><collection>Public Health Database</collection><collection>ProQuest SciTech Collection</collection><collection>ProQuest Natural Science Collection</collection><collection>Hospital Premium Collection</collection><collection>Hospital Premium Collection (Alumni Edition)</collection><collection>ProQuest Central (Alumni) (purchase pre-March 2016)</collection><collection>Research Library (Alumni Edition)</collection><collection>ProQuest Central (Alumni Edition)</collection><collection>ProQuest Central UK/Ireland</collection><collection>ProQuest Central Essentials</collection><collection>Biological Science Collection</collection><collection>ProQuest Central</collection><collection>Natural Science Collection</collection><collection>ProQuest One Community College</collection><collection>ProQuest Central Korea</collection><collection>Health Research Premium Collection</collection><collection>Health Research Premium Collection (Alumni)</collection><collection>ProQuest Central Student</collection><collection>Research Library Prep</collection><collection>AIDS and Cancer Research Abstracts</collection><collection>SciTech Premium Collection</collection><collection>ProQuest Health & Medical Complete (Alumni)</collection><collection>ProQuest Biological Science Collection</collection><collection>Health & Medical Collection (Alumni Edition)</collection><collection>Medical Database</collection><collection>Research Library</collection><collection>Biological Science Database</collection><collection>Research Library (Corporate)</collection><collection>Access via ProQuest (Open Access)</collection><collection>ProQuest One Academic Eastern Edition (DO NOT USE)</collection><collection>ProQuest One Academic</collection><collection>ProQuest One Academic UKI Edition</collection><collection>ProQuest Central China</collection><collection>ProQuest Central Basic</collection><jtitle>Tumor biology</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Vieira De Castro, Joana</au><au>Gonçalves, Céline S</au><au>Costa, Sandra</au><au>Linhares, Paulo</au><au>Vaz, Rui</au><au>Nabiço, Ricardo</au><au>Amorim, Júlia</au><au>Viana-pereira, Marta</au><au>Reis, Rui M</au><au>Costa, Bruno M</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Impact of TGF-[beta]1 -509C/T and 869T/C polymorphisms on glioma risk and patient prognosis</atitle><jtitle>Tumor biology</jtitle><date>2015-08-01</date><risdate>2015</risdate><volume>36</volume><issue>8</issue><spage>6525</spage><pages>6525-</pages><issn>1010-4283</issn><eissn>1423-0380</eissn><abstract>Transforming growth factor beta (TGF-[beta]) plays an important role in carcinogenesis. Two polymorphisms in the TGF-[beta]1 gene (-509C/T and 869T/C) were described to influence susceptibility to gastric and breast cancers. The 869T/C polymorphism was also associated with overall survival in breast cancer patients. In the present study, we investigated the relevance of these TGF-[beta]1 polymorphism in glioma risk and prognosis. A case-control study that included 114 glioma patients and 138 cancer-free controls was performed. Single nucleotide polymorphisms (SNPs) were evaluated by polymerase chain reaction followed by restriction fragment length polymorphism (PCR-RFLP). Univariate and multivariate logistic regression analyses were used to calculate odds ratio (OR) and 95 % confidence intervals (95 % CI). The influence of TGF-[beta]1-509C/T and 869T/C polymorphisms on glioma patient survival was evaluated by a Cox regression model adjusted for patients' age and sex and represented in Kaplan-Meier curves. Our results demonstrated that TGF-[beta]1 gene polymorphisms -509C/T and 869T/C are not significantly associated with glioma risk. Survival analyses showed that the homozygous -509TT genotype associates with longer overall survival of glioblastoma (GBM) patients when compared with patients carrying CC+CT genotypes (OR, 2.41; 95 % CI, 1.06-5.50; p=0.036). In addition, the homozygous 869CC genotype is associated with increased overall survival of GBM patients when compared with 869TT+TC genotypes (OR, 2.62; 95 % CI, 1.11-6.17; p=0.027). In conclusion, this study suggests that TGF-[beta]1-509C/T and 869T/C polymorphisms are not significantly associated with risk for developing gliomas but may be relevant prognostic biomarkers in GBM patients.</abstract><cop>London</cop><pub>Springer Nature B.V</pub><doi>10.1007/s13277-015-3343-0</doi><oa>free_for_read</oa></addata></record> |
| fulltext | fulltext |
| identifier | ISSN: 1010-4283 |
| ispartof | Tumor biology, 2015-08, Vol.36 (8), p.6525 |
| issn | 1010-4283 1423-0380 |
| language | eng |
| recordid | cdi_proquest_journals_1706017487 |
| source | SpringerNature Journals |
| subjects | Brain cancer Genotype & phenotype Growth factors Medical prognosis Polymorphism Risk factors |
| title | Impact of TGF-[beta]1 -509C/T and 869T/C polymorphisms on glioma risk and patient prognosis |
| url | https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2024-12-24T03%3A47%3A50IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Impact%20of%20TGF-%5Bbeta%5D1%20-509C/T%20and%20869T/C%20polymorphisms%20on%20glioma%20risk%20and%20patient%20prognosis&rft.jtitle=Tumor%20biology&rft.au=Vieira%20De%20Castro,%20Joana&rft.date=2015-08-01&rft.volume=36&rft.issue=8&rft.spage=6525&rft.pages=6525-&rft.issn=1010-4283&rft.eissn=1423-0380&rft_id=info:doi/10.1007/s13277-015-3343-0&rft_dat=%3Cproquest%3E3785385251%3C/proquest%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=1706017487&rft_id=info:pmid/&rfr_iscdi=true |